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Background: Cellfood™ (CF) is a nutritional supplement containing deuterium sulphate, minerals, amino acids, and
enzymes, with well documented antioxidant properties. Its organic and inorganic components are extracted from
the red algae Lithothamnion calcareum, whose mineral extract has shown growth-inhibitory effect both on in vitro
and in vivo models. The purpose of this study was to evaluate the antiproliferative effects of CF on leukemic cells. In
fact, according to its capacity to modulate O2 availability and to improve mitochondrial respiratory metabolism, we
wondered if CF could affect cancer cell metabolism making cells susceptible to apoptosis.
Methods: Three leukemic cell lines, Jurkat, U937, and K562, were treated with CF 5 μl/ml up to 72 hours. Cell
viability, apoptosis (i.e. caspase-3 activity and DNA fragmentation), hypoxia inducible factor 1 alpha (HIF-1α)
concentration, glucose transporter 1 (GLUT-1) expression, lactate dehydrogenase (LDH) activity and lactate release
in the culture medium were detected and compared with untreated cells.
Results: CF significantly inhibited leukemic cell viability by promoting cell apoptosis, as revealed by caspase-3
activation and DNA laddering. In particular, CF treated cells showed lower HIF-1α levels and lower GLUT-1
expression as compared to untreated cells. At the same time, CF was able to reduce LDH activity and,
consequently, the amount of lactate released in the extracellular environment.
Conclusions: We supplied evidence for an antiproliferative effect of CF on leukemia cell lines by inducing cell
death through an apoptotic mechanism and by altering cancer cell metabolism through HIF-1α and GLUT-1
regulation. Thanks to its antioxidative and proapoptotic properties, CF might be a good candidate for cancer
prevention.
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Cell proliferation, that represents the essence of cancer
disease, involves not only a deregulated control of cell
cycle but also adjustments of energy metabolism in
order to fuel cell growth and division. In fact, prolifera-
tion of cancer cells is accompanied by glycolysis activa-
tion and this altered glucose metabolism is one of the* Correspondence: serena.benedetti@uniurb.it
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stated.most common hallmark of cancer [1,2]. Approximately 60
to 90% of cancers display a metabolic profile, the so-called
Warburg phenotype, characterized by their dependence
upon glycolysis as the major source of energy, irrespective
of the oxygen level [3]. According to the Warburg effect,
cancer cells up-regulate glucose transporters, notably
GLUT-1, and convert pyruvate, the end-product of
glycolysis, into lactate by lactate dehydrogenase (LDH),
rather than oxidizing it in mitochondria [4-6].
In this context, the hypoxia inducible factor 1 (HIF-1)
has been shown to play a fundamental role [7,8]. HIF-1
is a transcription factor that consists of an O2-regulatedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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In cancer cells, HIF-1α is up-regulated and, in turn, acti-
vates the expression of glycolytic enzymes (such as
LDH) and glucose transporters (such as GLUT-1), and
down-regulates the mitochondrial activity through sev-
eral mechanisms, in particular by inhibiting the conver-
sion of pyruvate to acetyl-CoA via the activation of the
gene encoding pyruvate dehydrogenase kinase 1 [7-10].
Shifting metabolism away from mitochondria (glucose
oxidation) and towards the cytoplasm (glycolysis) might
suppress apoptosis, a form of cell death that is dependent
on mitochondrial energy production [11,12]. Accordingly,
the glycolytic phenotype has been associated to apoptosis
resistance and consequently increased tumor cell prolifer-
ation [3,4,13].
Understanding the metabolic basis of cancer has the
potential to provide the foundation for the development
of novel approaches targeting tumor metabolism [14].
In this regard, recent observations suggest that the re-
version of the glycolytic phenotype may render tumor
cells susceptible to apoptosis and decrease their growth
rate [15-17].
With this in mind, we planned to investigate whether
the natural supplement Cellfood™ (CF; Nu Science Cor-
poration, CA, USA) might have antiproliferative effects
in vitro, limiting cell proliferation and promoting cell
death. CF is a proprietary formulation containing 78
ionic/colloidal trace elements and minerals combined
with 34 enzymes and 17 amino acids, all suspended in a
solution of deuterium sulphate [18]. The organic and
inorganic components of the supplement are extracted
from the marine red algae Lithothamnion calcareum,
whose mineral extract has shown growth-inhibitory
effects on human colon carcinoma cells [19] as well as
inhibition of liver tumor formation in C57BL6 mice [20].
Referring to CF formulation, previous studies have
demonstrated its ability to furnish effective in vitro anti-
oxidant protection [21]. At the same time, the capability
of CF to modulate O2 availability and mitochondrial re-
spiratory metabolism has been evidenced in endothelial
cells [22].
All these observations led us to investigate the poten-
tial role of CF as hypoproliferative agent in vitro. For this
purpose, we analyzed the effect of CF on cell growth,
viability, glycolytic profile, and apoptosis on three hu-
man leukemia cell lines, Jurkat, U937, and K562. Eight-
een percent of malignancies are of hematological origin
[17]; moreover, leukemic cells are highly glycolytic [23],
though these cells reside within the bloodstream at
higher oxygen tensions than cells in most normal tissue.
In the present study we reported evidence that CF
showed antiproliferative effect on the above mentioned
leukemia cell lines due to apoptosis induction and tumor
metabolism modifications.Methods
Cellfood™
The supplement (liquid) was kindly provided by
Eurodream srl (La Spezia, Italy) and stored at room
temperature. CF was diluted in phosphate buffered sa-
line (PBS) and sterilized using a 0.45 μm syringe-filter
before use.
Cell culture
Three human leukemia cell lines were used in this study,
Jurkat (acute lymphoblastic leukemia), U937 (acute mye-
loid leukemia), and K562 (chronic myeloid leukemia in
blast crisis). Cells were grown in RPMI 1640 medium
supplemented with 10% heat-inactivated fetal bovine
serum, 1% L-glutamine and 1% penicillin/streptomycin
100 U/ml, and incubated in a CO2 incubator (37°C, 5%
CO2 and humidified atmosphere). Cell culture reagents
were from VWR International (Milan, Italy).
Lymphocytes were isolated from blood samples pro-
vided by healthy volunteers by centrifugation in the
presence of Lymphoprep™ (Axis-Shield PoC AS, Oslo,
Norway), and were cultured as described above with the
addition of 10 μg/ml of phytohemagglutinin (Sigma-
Aldrich, Milan, Italy).
A single dose of CF (final concentration 5 μl/ml) was
administered to leukemia cells or lymphocytes; cells
were collected after 24, 48, and 72 h of CF administra-
tion. Untreated cells served as controls. Trypan blue cell
counting was performed at each experimental time point
to evaluate the viable cell number.
Cell viability assay
Cell proliferation and viability were analyzed at 450 nm by
the WST-1 reagent (4-[3-(4-lodophenyl)-2-(4-nitrophenyl)-
2H-5-tetrazolio]-1,3-benzene disulfonate) (Roche Diagnos-
tics GmbH, Mannheim, Germany). The assay was based
on the cleavage of the tetrazolium salt WST-1 by mito-
chondrial dehydrogenases in viable cells. Briefly, leukemia
cells were incubated in 96-well plates in the presence or
absence of CF (5 μl/ml); after 24, 48, and 72 h of incuba-
tion, WST-1 was added to each well, and cells were further
incubated at 37°C up to 2 h. Colour development was
monitored at 450 nm in a multiwell plate reader (Thermo
Fisher Scientific, Shangai).
Caspase-3 activity evaluation
Caspase-3 activity was determined in leukemia cells
using a colorimetric kit from Biovision (Milpitas, CA,
USA) in accordance with the manufacturer’s instruc-
tions. The assay is based on the spectrophotometric de-
tection at 405 nm of the chromophore p-nitroaniline
(pNA) after cleavage from the labeled substrate DEVD-
pNA by caspase-3. Protein concentration in the cytosolic
extracts was measured using the Bradford method [24].
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The genomic DNA fragmentation was evaluated by
agarose gel electrophoresis of DNA isolates obtained by
the salting-out method [25]. For this purpose, leukemia
cells were grown in the presence or absence of CF 5 μl/ml
up to 72 h; a positive control (cells treated for 6 h with
25 μM etoposide) was also included. After counting
and washing, cells were subjected to DNA extraction.
The DNA samples were carefully resuspended in TE
buffer; the nucleic acid concentration and purity were
measured using a NanoDrop® ND-1000 spectrophotom-
eter (Thermo-Scientific, Wilminton, DE, USA). 2 μg of
each sample was loaded onto 1.5% TAE agarose gel;
DNA laddering was visualized on a UV transilluminator
by ethidium bromide staining. Images were obtained
using a Gel Doc 2000 (Bio-Rad Laboratories S.r.l,
Segrate, MI, Italy).HIF-1α measurement
HIF-1α quantification was performed in leukemia cells
using an enzyme-linked immunosorbent assay kit from
Abcam (Cambridge, UK), in accordance with the manu-
facturer’s instructions. Colour development was evalu-
ated at 450 nm in a multiwell plate reader (Thermo
Fisher Scientific, Shangai). Protein concentration in cell
extracts was measured using the Bradford method [24].Western blot assay of GLUT-1
Leukemia cells were grown in presence or absence of
CF 5 μl/ml up to 72 h. After counting and washing,
cells were resuspended in 1X SDS loading buffer to
20x106 cells/ml. Cell lysis was achieved by vortex, and
the viscosity was reduced by passing through a syringe
needle. 15 μl of each samples were run on 0.8% SDS-
polyacrylamide gel and the resolved proteins were elec-
trophoretically transferred to supported nitrocellulose
membranes (Bio-Rad Laboratories S.r.l, Segrate, MI,
Italy) using a Bio-Rad Semidry Transfer system. Non-
specific binding to membranes was blocked by incuba-
tion in blocking solution (50 mM Tris–HCl, 150 mM
NaCl and 5% (w/v) non-fat dried milk, pH 7.5). After
blocking solution removal, membranes were incubated
in a new blocking solution with a rabbit polyclonal
GLUT-1 antibody (PA1-46152, Thermo Scientific) at 4°C
overnight. Membranes were then washed three times
with TTBS (50 mM Tris–HCl, 150 mM NaCl and
0.05% (v/v) Tween 20, pH 7.5) and incubated with
horseradish peroxidase-conjugated anti-rabbit second-
ary antibody diluted 1:4500 in TTBS for 1 h at room
temperature. After TTBS washes, the blot was incu-
bated in detection reagent (ECL Advance Western Blot-
ting Detection Kit) and exposed to a Hyperfilm ECL
film (Pierce).LDH activity and lactate release measurement
After 72 h of incubation in the presence or absence of CF
(5 μl/ml), leukemia cells were centrifuged at 450 g for
10 min at room temperature; supernatants were collected
to evaluate lactate release in the culture media while cell
pellets were used for LDH activity determination.
Lactate measurement was performed through an en-
zymatic assay in a hydrazine/glycine buffer (pH 9.2),
containing 2 mg/ml β-NAD+ and 16 units/ml LDH [26].
The absorbance due to NADH formation was monitored
spectrophotometrically at 340 nm and the amount of
lactate released in the media was calculated using the
molar extinction coefficient of NADH.
To test LDH activity, cell pellets were washed once
with PBS by centrifugation at 450 g for 10 min at 4°C.
Supernatants were discarded and pellets resuspended in
a lysis buffer (CellLytic M reagent, Sigma-Aldrich,
Milan, Italy) containing a specific protease inhibitor
cocktail (Sigma-Aldrich, Milan, Italy). After 15 min incu-
bation, lysed cells were centrifuged at 12,000 g for
15 min at 4°C. The protein-containing supernatants were
used for LDH activity measurement as previously de-
scribed [27]. The assay medium contained 50 mM Tris–
HCl, pH 8, 0,2 mM β-NADH, and 5 mM pyruvate. The
oxidation of NADH was monitored as a decrease in
340 nm absorbance at 37°C. Protein concentration in cell
lysates was measured using the Bradford method [24].
Statistical analysis
The data are presented as the mean ± standard deviation
of at least three experiments and analyzed using
Student’s t-test. Significance level was set at p < 0.05 for
all analysis.
Results and discussion
Over the last decades, many studies using animal
models have shown numerous dietary constituents
and nutraceuticals as cancer chemopreventive agents
[28]; in fact, it has been generally accepted that they
can suppress transformation, hyperproliferation, inva-
sion, angiogenesis and metastasis of various tumors
[29]. Because oxidative and inflammatory stress con-
tributes to malignant transformation, dietary agents with
antioxidative, anti-inflammatory and proapoptotic proper-
ties would be good candidates for preventing human
malignancies [30-33].
Cellfood™ is a nutritional supplement whose antioxi-
dant properties have been well documented in vitro [21].
In the present study, we demonstrated for the first time
that in leukemia cell lines (Jurkat, U937, and K562) CF
treatment reduced cancer cell proliferation and viability
without affecting healthy lymphocyte growth. In fact, CF
administration at the concentration of 5 μl/ml induced a
significant reduction of leukemia cell growth as revealed
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cancer cell growth was maximum after 72 h, reaching
up to 50% inhibition in U937 cell line. Cell viability was
also evaluated through the measurement of mitochon-
drial dehydrogenase activity using the colorimetric
WST-1 assay (Figure 1B). Data confirmed that CF treat-
ment induced cell viability inhibition up-and-over 60%
in U937 cells after 72 h of incubation. To investigate the
selectivity of CF treatment towards tumor cells, human
healthy lymphocytes were seeded in the presence of the
same concentration of CF up to 96 h; data revealed no
significant differences between untreated and treated
cells, confirming that CF did not affect healthy lympho-
cyte growth (Figure 2).
These results are in accordance with the growth-
inhibitory properties of Lithothamnion calcareum, the red
algae from which the organic and inorganic components
of CF are extracted [19,20]. Indeed, the mineral-rich ma-
terial derived from the algae has been shown to suppress
the growth of a series of human colon cancer cell lines
in vitro [19], as well as to protect mice against neoplastic










































































Figure 1 Significant inhibition of leukemia cell proliferation (A) and v
comparison with untreated cells (control), as evaluated by cell counti
Data are expressed as mean ± SD of at least three independent experimenTo clarify whether CF was able to reduce cancer cell
viability by promoting apoptotic cell death, two classical
markers of apoptosis were determined. Caspase-3 is con-
sidered to be the most important effector of apoptosis
and a marker for both intrinsic and extrinsic pathways
[11]. Noteworthy, we evidenced that CF treatment
significantly stimulated caspase-3 activity in the three
leukemia cell lines as compared to the respective un-
treated controls (Figure 3).
On the other hand, the detection of the internucleosomal
DNA cleavage (or DNA laddering) is a common hallmark
of cells undergoing late-stage apoptosis [11]. To verify if
CF could induce DNA fragmentation and thus to confirm
whether apoptosis occurred, leukemia cells exposed to CF
treatment were assessed for DNA laddering by agarose gel
electrophoresis (Figure 4). We found that the three cell
lines incubated with CF showed apoptotic DNA fragmen-
tation profiles similar to the positive control, which was
represented by cells incubated with etoposide that is com-
monly known to be an apoptosis inducer [34]. On the
contrary, no nucleic acid fragmentation was observed
















iability (B) after 24, 48, and 72 h of incubation with CF in
ng by trypan blue dye exclusion and WST-1 reagent, respectively.































Figure 2 Lymphocyte cell growth in the presence of CF (5 μl/ml) in comparison with untreated cells (control). No effects were observed
up to 96 h after CF administration to isolated lymphocytes as a non-tumor cell system Data are expressed as mean ± SD of at least three
independent experiments.
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growth inhibition is occurred by the promotion of
apoptosis.
Then we wondered if apoptosis induction by CF was
related to HIF-1α regulation; in fact, this transcription
factor, by inhibiting the conversion of pyruvate to acetyl-
CoA via the activation of pyruvate dehydrogenase kinase
1, leads to a decrease of mitochondrial oxidative phos-
phorylation and, consequently, to tumor cell resistance
to apoptosis [35]. Our data revealed that CF treatment
led to a significant reduction of HIF-1α concentration in
comparison with untreated cells (Figure 5). The reduc-
tion of the transcription factor reached up to 40% in
U937 cell line. Consequently, decreased levels of HIF-1α
in leukemia cells treated with CF could be reasonably






























Figure 3 Significant increment of caspase-3 activity in leukemia cells af
with untreated cells (control). Data are expressed as mean ± SD of at leastglycolysis to oxidative phosphorylation), making them
susceptible to cell death, depending apoptosis on mito-
chondrial ATP production [11]. Based on our evidence,
further studies should be conducted to confirm the
activation of mitochondrial oxidative metabolism in
cancer cells upon CF administration; nonetheless, in
support of this hypothesis, previous observations indi-
cated that CF administration to normal endothelial
cells (HUVEC) allowed optimal O2 consumption by
improving respiratory metabolism and mitochondrial
activity [22].
Aerobic glycolysis not only provides ATP as a source
of energy but also precursors and reducing equivalents
for the synthesis of macromolecules [36]; therefore, glu-
cose uptake via GLUT-1 receptor is greatly enhanced in








ter 24, 48, and 72 h of incubation with CF (5 μl/ml) in comparison
three independent experiments. *p < 0.05 vs. untreated cells.
U937 K562JURKAT
1 2 3 4 1  2  3 41  2 3 4
Figure 4 DNA fragmentation of leukemia cells after 72 h of
incubation with CF (5 μl/ml). Apoptotic DNA fragmentation was
qualitatively analyzed by agarose gel electrophoresis. Lane 1: 1 kb
DNA ladder marker; lane 2: negative control (untreated cells); lane 3:
CF treated cells; lane 4: positive control (etoposide).
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neoplastic drug development; in fact, the acquisition of
the glycolytic phenotype has been shown to correlate
with increased tumor aggressiveness and poor patient
prognosis in several tumor types [37]. We evaluated the
expression of this glucose transporter by immunoblot
analysis after cancer cell incubation with CF. The densi-
tometric analysis of the bands revealed a lower GLUT-1
expression in the three leukemia cell lines in comparison
with untreated cells (Figure 6), thus indicating decreased
glucose uptake in CF treated cells. The reduction of
GLUT-1 expression as a consequence of CF administra-





























Figure 5 Significant decrease of HIF-1α concentration in leukemia cel
untreated cells (control). Data are expressed as mean ± SD of at least thrOther than GLUT-1 up-regulation, the activation of
HIF-1 also contributes to the conversion of glucose to
lactate. In fact, when stabilized, HIF-1α is directly in-
volved in the overexpression of many glycolytic enzymes
as well as LDH, the NADH-dependent enzyme that cata-
lyzes the conversion of pyruvate to lactate [38]. Based on
the observed strong LDH dependency for tumor prolif-
eration from both in vitro and in vivo studies [39,40], in-
hibition of LDH may represent an alternative strategy
toward the development of anti-glycolytic-based thera-
peutic strategies for the treatment of cancer. Note-
worthy, our data revealed that CF induced a significant
decrease in LDH activity after 72 hours from its admin-
istration (up to 28%) (Figure 7A). At the same time, the
amount of lactate released in the extracellular environ-
ment was also reduced in CF treated cells as compared
to untreated cells (up to 37%) (Figure 7B).
The reversion of the glycolytic phenotype is known to
render tumor cells susceptible to apoptosis and decrease
their growth rate [15-17]. In this context, our findings
are in accord with recent observations indicating that
the in vitro inhibition of tumor cell survival (T cell
lymphoma) by compounds targeting tumor metabolism
was accompanied by a modulation of lactate concentra-
tion in the tumor-conditioned medium, by altered
expression of HIF-1α and by an alteration in the expres-
sion of apoptotic (such as caspase-3) and cell survival
regulatory molecules (such as GLUT-1) [17].
Another important control point might be the glyco-
lytic enzyme glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) [41]. If the oxygen supply is normal, NADH
reducing equivalents that are generated by GAPDH are
transported inside the mitochondria in order to reach
the respiratory chain. In hypoxic conditions, the above
reducing equivalents are used by LDH to convertU937 K562
*
*
ls after 72 h of incubation with CF (5 μl/ml) in comparison with
ee independent experiments. *p < 0.05 vs. untreated cells.
Figure 6 Western Blotting analysis of GLUT-1 receptor in Jurkat,
U937, and K562 leukemia cell lines after 72 h of incubation with
CF (5 μl/ml) as compared to untreated cells (control). Results are
representative of three independent experiments.
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the mitochondria. This reaction is prominent in tumor
cells, thus the evaluation of CF effect on GAPDH activ-
ity could also be of great interest.
Being CF a nutritional supplement that contains differ-
ent active principles including deuterium sulphate,
minerals, amino acids and enzymes (Everett Storey’s
formula), at the moment we hypothesize that the herein
described effects on leukemic cells might depend on the
whole formula rather than on one or more particular
components.
We also observed that the three leukemia cell lines
showed different responses after CF treatment. In par-




















































Figure 7 LDH activity (A) and lactate release in the culture medium (B)
comparison with untreated cells (control). Data are expressed as mean ± Supon CF administration, showing the highest reduction
of cell viability as well as the highest caspase-3 activation
and GLUT-1 expression decrease, as compared to Jurkat
and K562 cells. These findings should be probably due
to the different metabolic features of the three leukemic
lines; in fact, Jurkat cells are an immortalized line of T
lymphocytes, while K562 and U937 cells are myeloge-
nous leukemia lines, the first with erythroid features and
the second with monocyte properties.
Conclusions
Modulation of cell signaling, apoptotic pathways and
tumor metabolism by dietary agents and nutraceutical
compounds may provide new opportunities in both pre-
vention and treatment of cancer. Herein we supply
evidence for a significant antiproliferative effect of the
nutritional supplement Cellfood™ on leukemia cell lines
by inducing cell death through an apoptotic mechanism
and by altering cell metabolism through HIF-1α and
GLUT-1 regulation. Thanks to its antioxidative and
proapoptotic properties, CF might be a good candidate
for cancer prevention. Large-scale clinical trials will be
needed to validate the usefulness of this agent either












in leukemia cells after 72 h of incubation with CF (5 μl/ml) in
D of at least three independent experiments. *p < 0.05 vs. untreated cells.
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